Submitted:
13 October 2025
Posted:
28 October 2025
You are already at the latest version
Abstract
Objectives: This study aimed to explore community pharmacists' experiences with non-codeine over-the-counter (OTC) cough syrup abuse among Nigerian youths aged 15-35, identify signs of misuse, assess barriers to intervention and reporting, and propose solutions to enhance pharmacovigilance (PV) practices. Methodology: A cross-sectional online survey was conducted from October 3rd – 12th, 2025 using a structured questionnaire with 15 multiple-choice and open-ended questions, distributed via Google Forms to 60 invited pharmacists across Lagos, Ogun, Ondo, Rivers, and Abuja. Forty-five active community pharmacists responded (75% response rate). Data were analysed using descriptive statistics (counts and percentages) in Microsoft Excel. Findings and Implications: Results indicated that 66.7% of pharmacists frequently or sometimes observed youths purchasing large quantities of syrups, with diphenhydramine implicated in 77.8% of suspected cases. Key signs included multiple bottle purchases (66.7%) and suspicious behaviour (66.7%). Barriers to prevention encompassed OTC regulations (44.4%) and lack of authority (22.2%), while none reported adverse drug reactions (ADRs) to NAFDAC due to unclear processes (33.3%). A significant association was found between pharmacists' experience (>5 years) and regular counselling. These findings highlight health implications such as increased risks of addiction, mental health disorders, and unreported ADRs, contributing to rising healthcare costs and youth morbidity. Socially, they exacerbate community stigma, economic burdens on families, and strain on public resources. By incorporating broader stakeholder perspectives (e.g., youths, regulators), the study underscores the need for policy reforms like prescription-only status for high-risk syrups and enhanced PV training, ultimately informing public health strategies to mitigate substance abuse in Nigeria.
Keywords:
Introduction
- What are the observed signs and frequency of non-codeine OTC cough syrup misuse among youths as reported by community pharmacists?
- What barriers do pharmacists face in preventing misuse and reporting ADRs to NAFDAC?
- How can stakeholder perspectives (e.g., from youths, regulators, and healthcare providers) inform strategies to improve PV and reduce abuse?
Methods
Sample and Data
Measures of Variables
Data Analysis Procedure
Results
Demographic Profile
Observations of Abuse
Challenges in Prevention
Counselling and Intervention Practices
Adverse Drug Reaction (ADR) Suspicion and Reporting
Proposed Strategies
Discussion
Conclusion
- Recommendations
- Policy: NAFDAC should enforce prescription-only for high-risk syrups and integrate stakeholder input (e.g., youths, retailers) in guidelines (National Agency for Food and Drug Administration and Control, 2025).
- Technology: Expand Med Safety App for seamless ADR reporting.
- Community: Launch multi-stakeholder campaigns involving healthcare providers, parents, and law enforcement.
- Questions for Further Research
- How does OTC cough syrup abuse vary across Nigeria's regions, and what local factors influence it?
- Can user-friendly reporting apps increase pharmacists' reporting of adverse effects?
- Does pharmacists' financial status affect their willingness to refuse suspicious sales?
- What are the long-term health impacts of non-codeine cough syrup abuse in youths?
- How can collaboration with mental health professionals or law enforcement support pharmacists in preventing abuse?
References
- Agada, P. O. , Eke, G. F., Adah, A. S., Enye, J. C., Nomor, E. D., & Terkula, D. B. Alterations in the biochemical indices in Wistar rats exposed to an over-the-counter cough syrup. Journal of Taibah University Medical Sciences 2021, 16, 424–431. [Google Scholar] [CrossRef]
- United Nations Office on Drugs and Crime. (2021). National Drug Control Master Plan (NDCMP) 2021–2025. https://www.unodc.org/documents/nigeria/NDCMP_2021-2025.
- Gobir, A. A. , Sambo, M. N., Bashir, S. S., Omole, N. V., Solanke, H. O., Salami, O. O., & Akande, T. M. The burden of drug abuse in Nigeria: A scoping review of epidemiological studies and drug laws. Public Health Reviews 2021, 42, 1603960. [Google Scholar] [CrossRef]
- Sessa, M. , Congiu, P., Piccoli, E., & Cipolla, G. Focus on over-the-counter drugs' misuse: A systematic review on antihistamines, cough medicines, and decongestants. Frontiers in Psychiatry 2021, 12, 657397. [Google Scholar] [CrossRef]
- Abubakar, A. R. , Simbak, N. B., & Haque, M. Factors that influence pharmacists' efforts in addressing substance use in Nigeria: An exploratory study of community pharmacists. Exploratory Research in Clinical and Social Pharmacy 2022, 6, 100153. [Google Scholar] [CrossRef]
- Garba, M. , Ogunyinka, I. A., & Ogunyinka, B. I. Prevalence and pattern of use of medications amongst undergraduate students of a Nigerian University. Medicine in Novel Technology and Devices 2023, 18, 100229. [Google Scholar] [CrossRef]
- Aina, B. A. , Ogunbiyi, O. O., & Adebayo, F. O. Perception of community pharmacists on abuse of psychotropic medications among the consumers. Tropical Journal of Pharmaceutical Research 2023, 22, 415–422. [Google Scholar] [CrossRef]
- Abdulaziz, M. , Alshammari, T. M., & Al-Kahtani, N. Combating opioid misuse in Nigeria: A comprehensive strategy for prevention and intervention. Addiction 2025, 120, 385–386. [Google Scholar] [CrossRef]
- ational Agency for Food and Drug Administration and Control. (2025). The year 2025 – NAFDAC Director General's strategic plan. https://nafdac.gov.ng/the-year-2025-nafdac-director-generals-strategic-plan/.
- Akunne, C. , Oweibia, M., Egberipou, T., Wilson, T. R., & Okafor, E. (2025). Drug abuse in Nigeria: The public health impact of substance use disorders. medRxiv. [CrossRef]
| Characteristic | Percentage (%) |
|---|---|
| Experience: Average 5.6 years (2-10) | - |
| Customers per day: 10-20 | 11.1 |
| 20-50 | 33.3 |
| 50-100 | 22.2 |
| 100-200 | 11.1 |
| Over 200 | 22.2 |
| Observation | Percentage (%) |
|---|---|
| Frequency: Weekly | 44.4 |
| Monthly | 22.2 |
| Rarely/Never | 33.3 |
| Misused Substance: Diphenhydramine | 77.8 |
| Dextromethorphan | 11.1 |
| Mixed | 11.1 |
| Signs: Frequent purchases | 77.8 |
| Multiple bottles | 66.7 |
| Suspicious behaviour | 66.7 |
| Mixing with alcohol/soda | 66.7 |
| Barrier | Percentage (%) |
|---|---|
| OTC regulations (no prescription) | 44.4 |
| Lack of authority to refuse | 22.2 |
| Fear of losing customers | 11.1 |
| Fear of harm | 11.1 |
| Combination of issues | 11.1 |
| Practice/Barrier | Percentage (%) |
|---|---|
| Always counsel | 44.4 |
| Sometimes counsel | 44.4 |
| Rarely counsel | 11.1 |
| Barriers: Lack of time | 33.3 |
| Lack of authority | 11.1 |
| Uneducated customers | 11.1 |
| Obtain elsewhere | 11.1 |
| Fear of attack | 11.1 |
| Lack of proof | 11.1 |
| Aspect | Percentage (%) |
|---|---|
| Suspected ADRs | 33.3 |
| Reported to NAFDAC | 0.0 |
| Reasons: Unclear processes | 33.3 |
| Lack of time | 22.2 |
| Fear of legal issues | 11.1 |
| No help | 11.1 |
| Other | 22.2 |
| Confidence: Very confident | 55.6 |
| Moderately confident | 44.4 |
| Strategy | Percentage (%) |
|---|---|
| Stricter OTC regulations | 77.8 |
| Mandatory counselling | 66.7 |
| Training to identify abuse | 55.6 |
| User-friendly apps | 44.4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).